1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Vifor Pharma AG - Product Pipeline Review - 2014

Vifor Pharma AG - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 27 pages

Vifor Pharma AG - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Vifor Pharma AG - Product Pipeline Review - 2014’, provides an overview of the Vifor Pharma AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vifor Pharma AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Vifor Pharma AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vifor Pharma AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Vifor Pharma AG’s pipeline products

Reasons to buy

- Evaluate Vifor Pharma AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vifor Pharma AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vifor Pharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vifor Pharma AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vifor Pharma AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vifor Pharma AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Vifor Pharma AG - Product Pipeline Review - 2014
Table of Contents

Vifor Pharma AG Snapshot 4
Vifor Pharma AG Overview 4
Key Information 4
Key Facts 4
Vifor Pharma AG - Research and Development Overview 5
Key Therapeutic Areas 5
Vifor Pharma AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Vifor Pharma AG - Pipeline Products Glance 11
Vifor Pharma AG - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Vifor Pharma AG - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Vifor Pharma AG - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Vifor Pharma AG - Drug Profiles 14
sucroferric oxyhydroxide 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ferric carboxymaltose 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
VIT-91 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Vifor Pharma AG - Pipeline Analysis 18
Vifor Pharma AG - Pipeline Products by Target 18
Vifor Pharma AG - Pipeline Products by Route of Administration 19
Vifor Pharma AG - Pipeline Products by Molecule Type 20
Vifor Pharma AG - Pipeline Products by Mechanism of Action 21
Vifor Pharma AG - Recent Pipeline Updates 22
Vifor Pharma AG - Dormant Projects 24
Vifor Pharma AG - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Vifor Pharma AG, Key Information 4
Vifor Pharma AG, Key Facts 4
Vifor Pharma AG - Pipeline by Indication, 2014 6
Vifor Pharma AG - Pipeline by Stage of Development, 2014 7
Vifor Pharma AG - Monotherapy Products in Pipeline, 2014 8
Vifor Pharma AG - Partnered Products in Pipeline, 2014 9
Vifor Pharma AG - Partnered Products/ Combination Treatment Modalities, 2014 10
Vifor Pharma AG - Phase III, 2014 11
Vifor Pharma AG - Phase I, 2014 12
Vifor Pharma AG - Preclinical, 2014 13
Vifor Pharma AG - Pipeline by Target, 2014 18
Vifor Pharma AG - Pipeline by Route of Administration, 2014 19
Vifor Pharma AG - Pipeline by Molecule Type, 2014 20
Vifor Pharma AG - Pipeline Products by Mechanism of Action, 2014 21
Vifor Pharma AG - Recent Pipeline Updates, 2014 22
Vifor Pharma AG - Dormant Developmental Projects,2014 24

List of Figures

Vifor Pharma AG - Pipeline by Top 10 Indication, 2014 6
Vifor Pharma AG - Pipeline by Stage of Development, 2014 7
Vifor Pharma AG - Monotherapy Products in Pipeline, 2014 8
Vifor Pharma AG - Partnered Products in Pipeline, 2014 9
Vifor Pharma AG - Pipeline by Top 10 Route of Administration, 2014 19
Vifor Pharma AG - Pipeline by Top 10 Molecule Type, 2014 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.